Every Form 4 that Immucell Corp (ICCC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ICCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ICCC filings page.
ImmuCell Corp director and CEO Paul Francis Olivier te Boekhorst reported buying additional company stock. On June 18, 2026, he made an open-market purchase of 8,000 shares of ImmuCell common stock at $9.495 per share, bringing his direct holdings to 17,785 shares.
ImmuCell Corporation director Kathy V. Turner received a grant of 17,899 non-qualified stock options. These options give her the right to buy an equal number of ImmuCell common shares at an exercise price of $7.60 per share and represent a compensation award rather than an open-market purchase.
The options vest over three years, with 5,966 options becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 options vesting on April 15, 2029. All of the options expire on April 15, 2036 if they are not exercised.
ImmuCell Corp director David Scott Tomsche received a grant of stock options as part of his compensation. He was awarded 11,933 non-qualified stock options to buy ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over time: 3,977 become exercisable on April 15, 2027, another 3,977 on April 15, 2028, and 3,979 on April 15, 2029. This is a compensation-related award, not an open-market purchase or sale of shares.
ImmuCell director Gloria F. Basse received a grant of 11,933 non-qualified stock options to buy ImmuCell common stock. The options have an exercise price of $7.60 per share and expire on April 15, 2036.
All 11,933 options were awarded as compensation and are held directly. According to the vesting schedule, 3,977 options become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 options become exercisable on April 15, 2029.
ImmuCell Corp director Paul R. Wainman received a new stock option grant as part of his compensation. He was awarded options to buy 11,933 shares of ImmuCell common stock at an exercise price of $7.60 per share, expiring on April 15, 2036.
The options vest over three years: 3,977 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 3,979 shares on April 15, 2029. After this grant, Wainman holds 11,933 stock options directly, indicating a compensation-related equity award rather than an open-market purchase or sale.
ImmuCell Corp. director Bryan K. Gathagan received a grant of non-qualified stock options for 10,000 shares of common stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this grant, he holds 10,000 options directly.
ImmuCell Corp. director Paul R. Wainman received a grant of stock options as part of his compensation. On April 16, 2025, he was awarded non-qualified options to acquire 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share.
The options become exercisable on April 16, 2028 and expire on April 16, 2030. Following this grant, Wainman holds 10,000 stock options directly, and this filing does not show any sales or open-market purchases of common stock.
ImmuCell Corp director David Scott Tomsche received a grant of 10,000 stock options as compensation. These non-qualified stock options give him the right to buy 10,000 shares of ImmuCell common stock at an exercise price of $5.49 per share. Following this award, his reported derivative holdings from this grant total 10,000 options, which become exercisable on April 16, 2028 and expire on April 16, 2030. This is a routine equity incentive award rather than an open-market share purchase or sale.
ImmuCell Corp. vice president Bobbi Jo Brockmann received a grant of 5,000 incentive stock options for company common stock. The options carry an exercise price of $5.49 per share and relate to 5,000 underlying common shares. They are reported as directly owned and expire on April 16, 2030.
ImmuCell Corp. director Steven T. Rosgen received a grant of 10,000 non-qualified stock options on Common Stock. The options have an exercise price of $5.49 per share, become exercisable on April 16, 2028, and expire on April 16, 2030. Following this compensation-related award, he holds 10,000 options directly.
ImmuCell Corp. director Gloria F. Basse received a grant of 10,000 non-qualified stock options on Common Stock. These options were awarded as compensation at an exercise price of $5.49 per share, allowing her to buy up to 10,000 shares at that price if she chooses to exercise.
After this award, she holds options on 10,000 shares in total, with the options scheduled to become exercisable on April 16, 2028 and expiring on April 16, 2030. This is a routine equity incentive grant rather than an open-market stock purchase or sale.
ImmuCell director Michael F. Brigham reported a routine stock option exercise. He exercised options for 25,000 shares of Common Stock at $5.84 per share, using previously owned shares to pay the exercise price. In connection with this, 24,052 shares were surrendered to the company to satisfy the option exercise price or related obligations. After these transactions, he directly holds 205,700 shares of ImmuCell Common Stock.
ImmuCell Corp filed an amended insider report showing that President and CEO Paul Francis Olivier te Boekhorst received a grant of 109,500 stock options on January 27, 2026 at an exercise price of $6.265 per share. This amendment corrects the previously reported number of options.
The options were granted in connection with his role as President and CEO. All of the options vest only if ImmuCell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year, making this a fully performance-based award.
ImmuCell Corporation filed a Form 4 for Chief Financial Officer and director Timothy C. Fiori reporting a new stock option grant. On January 27, 2026, he received 120,000 stock options with an exercise price of $6.265 per share, held directly.
The option is intended to qualify as an incentive stock option to the maximum extent allowed under the Internal Revenue Code, with the remainder as a nonqualified option. It vests in three equal tranches of 40,000 options on each of the first, second, and third anniversaries of the grant date.
ImmuCell Corporation filed a Form 4 showing an option grant to executive and director Bobbi Jo Brockmann. On January 27, 2026, she received stock options to purchase 100,000 shares of common stock at an exercise price of $6.265 per share, expiring on January 27, 2036.
The options were granted in connection with her role as Vice President of Sales and Marketing. They vest over three years: 33,333 shares become exercisable on each of January 27, 2027 and January 27, 2028, and 33,334 shares become exercisable on January 27, 2029. Following this grant, she beneficially owns 100,000 derivative securities directly.
Immucell Corporation reported a new equity award to its President and CEO, Paul Francis Olivier te Boekhorst. On January 27, 2026, he was granted 110,000 stock options with an exercise price of $6.265 per share.
The option is intended to qualify as an incentive stock option to the maximum extent allowed, with any remainder treated as a nonqualified option. All of the options will vest only if Immucell’s net operating income for four consecutive calendar quarters reaches at least 300% of its audited net operating income for the 2025 fiscal year.
ImmuCell Corp (ICCC) reported a Form 4 showing its President and CEO (also a Director) received a grant of 74,277 stock options at an exercise price of $6.10 on November 7, 2025.
The options vest in three equal tranches of 24,759 on the first, second, and third anniversaries of the grant and expire on November 7, 2035. The award will be treated as an incentive stock option to the maximum extent permitted, with the balance as a nonqualified option. Following the grant, the officer beneficially owned 150,260 derivative securities.